|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
19
|
|
pubmed:dateCreated |
2000-11-21
|
|
pubmed:abstractText |
Most nonsteroidal anti-inflammatory drugs (NSAIDs) are nonselective cyclooxygenase (COX-1 and COX-2) inhibitors and are associated with a variety of upper gastrointestinal (GI) tract symptoms. The roles of COX-1 and COX-2 in the pathogenesis of these symptoms are unclear. To test whether COX-2 inhibition with rofecoxib would have greater GI tolerability than nonselective COX-1 and COX-2 inhibition, we compared the incidences of (1) treatment discontinuations for GI adverse events (AEs) and (2) prespecified dyspeptic-type GI AEs among patients with osteoarthritis treated with rofecoxib vs NSAIDs.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Anti-Inflammatory Agents...,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclooxygenase 1,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclooxygenase 2,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclooxygenase 2 Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclooxygenase Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Isoenzymes,
http://linkedlifedata.com/resource/pubmed/chemical/Lactones,
http://linkedlifedata.com/resource/pubmed/chemical/Membrane Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/PTGS1 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/PTGS2 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Prostaglandin-Endoperoxide Synthases,
http://linkedlifedata.com/resource/pubmed/chemical/Sulfones,
http://linkedlifedata.com/resource/pubmed/chemical/rofecoxib
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
0003-9926
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
23
|
|
pubmed:volume |
160
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2998-3003
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:11041909-Abdominal Pain,
pubmed-meshheading:11041909-Adult,
pubmed-meshheading:11041909-Aged,
pubmed-meshheading:11041909-Aged, 80 and over,
pubmed-meshheading:11041909-Anti-Inflammatory Agents, Non-Steroidal,
pubmed-meshheading:11041909-Clinical Trials, Phase II as Topic,
pubmed-meshheading:11041909-Clinical Trials, Phase III as Topic,
pubmed-meshheading:11041909-Cyclooxygenase 1,
pubmed-meshheading:11041909-Cyclooxygenase 2,
pubmed-meshheading:11041909-Cyclooxygenase 2 Inhibitors,
pubmed-meshheading:11041909-Cyclooxygenase Inhibitors,
pubmed-meshheading:11041909-Dyspepsia,
pubmed-meshheading:11041909-Female,
pubmed-meshheading:11041909-Humans,
pubmed-meshheading:11041909-Isoenzymes,
pubmed-meshheading:11041909-Lactones,
pubmed-meshheading:11041909-Male,
pubmed-meshheading:11041909-Membrane Proteins,
pubmed-meshheading:11041909-Middle Aged,
pubmed-meshheading:11041909-Osteoarthritis,
pubmed-meshheading:11041909-Prostaglandin-Endoperoxide Synthases,
pubmed-meshheading:11041909-Randomized Controlled Trials as Topic,
pubmed-meshheading:11041909-Sulfones
|
|
pubmed:year |
2000
|
|
pubmed:articleTitle |
Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis.
|
|
pubmed:affiliation |
Merck Research Labs, West Point, PA, USA.
|
|
pubmed:publicationType |
Journal Article,
Meta-Analysis
|
